Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroinflammation and Brain Disease.

BMC neurology·2023
Same author

Cognitive aspects of MELAS and CARASAL.

Cerebral circulation - cognition and behavior·2022
Same author

Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.

Journal of neuroimmunology·2021
Same author

The Genetic Basis of Moyamoya Disease.

Translational stroke research·2021
Same author

A Multidisciplinary Evaluation of Patients with DMD in An Italian Tertiary Care Center.

Journal of neuromuscular diseases·2020
Same author

Correction to: Heritable and non-heritable uncommon causes of stroke.

Journal of neurology·2020

Related Experiment Video

Updated: Jul 5, 2026

Transient Middle Cerebral Artery Occlusion Model of Stroke
05:32

Transient Middle Cerebral Artery Occlusion Model of Stroke

Published on: August 11, 2023

Genetic polymorphisms for the study of multifactorial stroke.

A Bersano1, E Ballabio, N Bresolin

  • 1Dipartimento di Scienze Neurologiche, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Università degli Studi di Milano, Milano, Italy.

Human Mutation
|April 19, 2008
PubMed
Summary

Genetic factors contribute to stroke risk, but single genes are rarely the cause. This review analyzes recent studies on multiple genes, identifying key variants associated with stroke to guide future research and clinical application.

Related Experiment Videos

Last Updated: Jul 5, 2026

Transient Middle Cerebral Artery Occlusion Model of Stroke
05:32

Transient Middle Cerebral Artery Occlusion Model of Stroke

Published on: August 11, 2023

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Epidemiology

Background:

  • Stroke is a complex trait, likely influenced by multiple genes rather than single-gene disorders.
  • Previous genetic association studies in stroke have yielded inconsistent and controversial results.
  • Clinicians face challenges in applying genetic findings to stroke risk assessment due to unclear validity.

Purpose of the Study:

  • To provide an updated and extensive analysis of recent genetic association studies in stroke.
  • To identify a definitive panel of genes and molecular variants associated with stroke risk.
  • To categorize these genetic factors based on their degree of association with stroke.

Main Methods:

  • Systematic review and analysis of recent association studies on candidate genes in stroke.
  • Evaluation of studies investigating genes such as F5, APOE, MTHFR, and others.
  • Categorization of genes and variants based on meta-analyses and case-control study results.

Main Results:

  • Identified a panel of candidate genes and molecular variants with varying degrees of association with stroke.
  • Synthesized evidence from numerous association studies, meta-analyses, and case-control studies.
  • Highlighted the polygenic nature of stroke and the complex interplay of genetic factors.

Conclusions:

  • The identified panel of genes and variants can guide future molecular investigations into stroke.
  • Findings facilitate more detailed meta-analyses to clarify genetic contributions to stroke.
  • This review aims to improve the clinical applicability of genetic data in stroke management.